Antares Pharma (NASDAQ: ATRS) reported Q4 EPS of ($0.08), $0.03 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $8.5 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.